Patrick J. T. Vallance
Director/Board Member at Office for Strategic Co-ordination of Health Research
Network origin in Patrick J. T. Vallance first degree
Entity | Entity type | Industry | |
---|---|---|---|
Office for Strategic Co-ordination of Health Research
2
| Non-Profit Organization | 2 |
Chart of Companies connected to the second degree
Multi-company connection
Companies connected to Patrick J. T. Vallance via their personal network
Company | Sector | Related people | Main position |
---|---|---|---|
Genentech, Inc.
Genentech, Inc. BiotechnologyHealth Technology Genentech, Inc. develops, manufactures and markets pharmaceutical products for life-threatening medical conditions. It studies various areas including oncology, immunology, neuroscience, ophthalmic diseases, microbial pathogenesis, metabolic diseases, cardiovascular diseases, and opportunistic areas. The company was founded by Herb W. Boyer and Robert A. Swanson in 1976 and is headquartered in South San Francisco, CA. | Biotechnology | Director/Board Member | |
ROCHE HOLDING AG | Pharmaceuticals: Major | Director/Board Member | |
F. Hoffmann-La Roche Ltd.
F. Hoffmann-La Roche Ltd. Pharmaceuticals: MajorHealth Technology F. Hoffmann-La Roche Ltd. manufactures pharmaceutical products. It offers pharmaceutical drugs, pharmaceutical instruments, and diagnostics solutions. The company was founded by Fritz Hoffmann-La Roche on October 1, 1896 and is headquartered in Basel, Switzerland. | Pharmaceuticals: Major | Director/Board Member | |
F-Star Biotechnologische Forschungs- Und Entwicklungsges MBH
F-Star Biotechnologische Forschungs- Und Entwicklungsges MBH Medical SpecialtiesHealth Technology F-Star Biotechnologische Forschungs- Und Entwicklungsges MBH develops improved therapeutic antibodies and antibody fragments for cancer. It is a biopharmaceutical company dedicated to developing novel bispecific antibody products that significantly improve on the current standard of care for patients with serious diseases such as cancer. The firm's modular antibody technology allows them to rapidly discover and develop bispecific antibodies by introducing additional binding sites to the constant region of an antibody. The company was founded by Florian Ruker, Gordana Wozniak-Knopp, and Gottfried Himmler on June 12, 2006 and is headquartered in Vienna, Austria. | Medical Specialties | Chief Executive Officer | |
Atlantic Healthcare Plc
Atlantic Healthcare Plc Pharmaceuticals: MajorHealth Technology Atlantic Healthcare Plc operates as holding company with interest in pharmaceutical. Its products include Alicaforsen Enema, an anti-inflammatory intercellular adhesion molecule inhibitor that acts by inhibiting a key protein in the inflammation process. The firm offers its product for the treatment of pouchitis and ulcerative colitis. The company was founded by Toby Wilson Waterworth and Fiona Mary Wilson Waterworth in 2006 and is headquartered in Saffron Walden, the United Kingdom. | Pharmaceuticals: Major | Director/Board Member | |
Oxford BioTherapeutics Ltd.
Oxford BioTherapeutics Ltd. Pharmaceuticals: MajorHealth Technology Oxford BioTherapeutics Ltd. develops antibody-based medicines for oncology. The firm offers antibody-based cancer drugs with integrated diagnostics against novel targets. The company was founded by Christian Rohlff in 2003 and is headquartered in Abingdon, the United Kingdom. | Pharmaceuticals: Major | Director/Board Member | |
GSK PLC | Pharmaceuticals: Major | Corporate Officer/Principal | |
University of Oxford | College/University | Corporate Officer/Principal | |
Magdalen College School Oxford Ltd | College/University | Undergraduate Degree | |
Oxagen Ltd.
Oxagen Ltd. Pharmaceuticals: MajorHealth Technology Oxagen Ltd. develops novel molecule drugs to treat inflammatory and respiratory diseases. It offers OC000459, an oral CRTH2 antagonist for the treatment of eosinophilic asthma and allergic rhino conjunctivitis. The company was founded by Nick Cross, John Irving Bellin, Mark Edwards, Trevor J. Nicholls and Ian Michael Laing on September 05 1996 and is headquartered in London, the United Kingdom. | Pharmaceuticals: Major | Founder | |
Rhodes Trust | Director/Board Member | ||
University of Alberta | College/University | Undergraduate Degree | |
Henley Management College | College/University | Masters Business Admin | |
AVACTA GROUP PLC | Miscellaneous Commercial Services | Chairman | |
Academy of Medical Sciences
Academy of Medical Sciences Miscellaneous Commercial ServicesCommercial Services The Academy of Medical Sciences was founded in 1998 and provides biomedical and health research services. The non-profit company is based in London, UK. | Miscellaneous Commercial Services | President | |
PROTALIX BIOTHERAPEUTICS, INC. | Pharmaceuticals: Major | Chairman | |
The Jenner Institute Laboratories
The Jenner Institute Laboratories Miscellaneous Commercial ServicesCommercial Services The Jenner Institute Laboratories engages in the development of vaccine against major diseases. The company was founded in November 2005 and is headquartered in Oxford, the United Kingdom. | Miscellaneous Commercial Services | Corporate Officer/Principal | |
The Wellcome Trust Centre for Human Genetics | Founder | ||
Oxford Centre for Diabetes Endocrinology & Metabolism | Corporate Officer/Principal | ||
Oxford University Hospitals NHS Trust | Investment Trusts/Mutual Funds | Director/Board Member | |
The Gray Laboratory Cancer Research Trust | Director/Board Member | ||
The Oxford Health Alliance
The Oxford Health Alliance Miscellaneous Commercial ServicesCommercial Services The Oxford Health Alliance is a British charitable company that focuses on preventing chronic diseases. The non-profit company is based in Greater London, UK. | Miscellaneous Commercial Services | Chairman | |
GMEC Management Co. Ltd. | Chairman | ||
The Ewelme Almshouse Charity | Director/Board Member | ||
Atopix Therapeutics Ltd.
Atopix Therapeutics Ltd. Pharmaceuticals: MajorHealth Technology Atopix Therapeutics Ltd. develops medicines to treat atopic dermatitis and severe asthma. The firm also assess the safety and pharmacokinetic profile of its back-up molecule ATX2417 in a phase I study. The company was incorporated on October 10, 2012 and is headquartered in Abingdon, the United Kingdom. | Pharmaceuticals: Major | Director/Board Member | |
F-star Alpha Ltd.
F-star Alpha Ltd. BiotechnologyHealth Technology F-star Alpha Ltd. develops novel bispecific antibody products. It focuses on treatment of breast and gastric cancer among a population of HER2-positive patients who do not respond or become resistant to current therapies. The company was founded in October 2013 and is headquartered in Cambridge, the United Kingdom. | Biotechnology | Director/Board Member | |
Genomics England Ltd.
Genomics England Ltd. Miscellaneous Commercial ServicesCommercial Services Genomics England Ltd. runs and delivers 100,000 genomes project. Its flagship project sequences 100,000 genomes from NHS patients with a rare disease and their families, and patients with cancer. The company was founded by Jeremy Hunt on July 5, 2013 and is headquartered in London, the United Kingdom. | Miscellaneous Commercial Services | Director/Board Member Director/Board Member | |
MedCity Ltd. | Chairman | ||
F-Star Beta Ltd.
F-Star Beta Ltd. BiotechnologyHealth Technology F-Star Beta Ltd. is a biopharmaceutical company that focused in the development of oncology and immune-oncology products. The company was founded on October 14, 2014 and is headquartered in Cambridge, the United Kingdom. | Biotechnology | Director/Board Member | |
Creabilis SA | Chief Executive Officer | ||
Avacta Life Sciences Ltd.
Avacta Life Sciences Ltd. Pharmaceuticals: MajorHealth Technology Avacta Life Sciences Ltd. provides powerful reagents for research and diagnostics. The company is headquartered in Wetherby, the United Kingdom. | Pharmaceuticals: Major | Chairman | |
SENSYNE HEALTH PLC | Miscellaneous Commercial Services | Chairman | |
F-Star Delta Ltd.
F-Star Delta Ltd. Pharmaceuticals: MajorHealth Technology Part of Sino Biopharmaceutical Ltd., F-Star Delta Ltd. develops antibody products to improve the treatment of serious diseases. The private company is based in Cambridge, UK and was founded in 2016. | Pharmaceuticals: Major | Director/Board Member | |
F-star Therapeutics Ltd.
F-star Therapeutics Ltd. Pharmaceuticals: MajorHealth Technology F-Star Therapeutics Ltd. is a biopharmaceutical company, which engages in the development of immune-oncology drugs for antibody therapies. The company was founded in 2006 and is headquartered in Cambridge, the United Kingdom. | Pharmaceuticals: Major | Chief Executive Officer | |
Ochre Bio Ltd.
Ochre Bio Ltd. Pharmaceuticals: MajorHealth Technology Ochre Bio Ltd. is a biotechnology company based in Headington, UK. Ochre Bio is focused on developing RNA medicines for chronic liver diseases. The British company uses deep phenotyping, precision RNA medicine, and testing in live human donor livers to develop therapies for important liver health challenges. The company's goal is to develop therapies that increase donor liver supply and reduce cirrhosis complications. The company was founded by Quin Wills and the CEO is Jack O'Meara. | Pharmaceuticals: Major | Chairman | |
IMMATICS N.V. | Biotechnology | Director/Board Member | |
F-STAR THERAPEUTICS, INC. | Pharmaceuticals: Major | Chief Executive Officer | |
IMMUNOCORE HOLDINGS PLC | Biotechnology | Chairman Chief Executive Officer | |
Spinifex Pty Ltd. | Director/Board Member | ||
Atlantic Pharmaceuticals (Holdings) Ltd. | Director/Board Member | ||
Immunocore Ltd.
Immunocore Ltd. Pharmaceuticals: MajorHealth Technology Part of Immunocore Holdings Plc, Immunocore Ltd. is a British commercial-stage biotechnology company that develops and commercializes transformative medicines to address unmet needs in cancer, infection, and autoimmune disease. The private company is based in Oxon, UK. The company has a robust pipeline of wholly owned and partnered programs to address a broad spectrum of disease indications, built on their proprietary soluble TCR bi-specific Immtac® platform. The company was founded in 2007, and the CEO is Bahija Jallal. | Pharmaceuticals: Major | Chief Executive Officer | |
Liverpool Health Partners Ltd. | Chairman | ||
Tessellate Bio BV
Tessellate Bio BV BiotechnologyHealth Technology Tessellate Bio BV is a Dutch preclinical stage biotechnology company that focuses on discovering and developing precision oncology medicines. The company is based in Naarden, the Netherlands. The company's mission is to turn cancer patients into cancer survivors by targeting unexplored or difficult to drug pathways beyond HRD. The company is also developing companion diagnostics, including a potentially diagnostic to detect ALT positive cancers. Led by an experienced team of drug hunters, Tessellate Bio is building a pipeline of first-in-class medicines based on cutting-edge research. The company was founded by Hilda A. Pickett and the CEO is Andree Blaukat. | Biotechnology | Director/Board Member | |
F-star Biotechnology Ltd.
F-star Biotechnology Ltd. BiotechnologyHealth Technology F-Star Biotechnology Ltd. is a biopharmaceutical company. It discovers, develops, and manufactures bispecific antibody products. The company is headquartered in Cambridge, the United Kingdom. | Biotechnology | Chief Executive Officer | |
Pfizer Holdings International Luxembourg (PHIL) SARL
Pfizer Holdings International Luxembourg (PHIL) SARL Financial ConglomeratesFinance Part of Pfizer Inc., Pfizer Holdings International Luxembourg (PHIL) SARL is an investment holding private company. The company is based in Luxembourg, Luxembourg. | Financial Conglomerates | Corporate Officer/Principal |
Statistics
International
United Kingdom | 36 |
United States | 5 |
Switzerland | 3 |
Australia | 3 |
Luxembourg | 3 |
Sectoral
Health Technology | 28 |
Commercial Services | 7 |
Consumer Services | 5 |
Miscellaneous | 2 |
Finance | 2 |
Operational
Director/Board Member | 33 |
Chief Executive Officer | 12 |
Chairman | 11 |
Corporate Officer/Principal | 7 |
Independent Dir/Board Member | 4 |
Most connected contacts
Insiders | |
---|---|
Eliot Forster | 35 |
John Bell | 27 |
- Stock Market
- Insiders
- Patrick J. T. Vallance
- Company connections